Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 191 entries
Sorted by: Best Match Show Resources per page
Transforming the Paradigm for Lipid Lowering.

JAMA cardiology

Navar AM, Fonarow GC.
PMID: 34550298
JAMA Cardiol. 2021 Dec 01;6(12):1414. doi: 10.1001/jamacardio.2021.3517.

No abstract available.

Cite
Navar AM, Fonarow GC. Transforming the Paradigm for Lipid Lowering. JAMA Cardiol. 2021;6(12):1414doi: 10.1001/jamacardio.2021.3517.
Navar, A. M., & Fonarow, G. C. (2021). Transforming the Paradigm for Lipid Lowering. JAMA cardiology, 6(12), 1414. https://doi.org/10.1001/jamacardio.2021.3517
Navar, Ann Marie, and Fonarow, Gregg C. "Transforming the Paradigm for Lipid Lowering." JAMA cardiology vol. 6,12 (2021): 1414. doi: https://doi.org/10.1001/jamacardio.2021.3517
Navar AM, Fonarow GC. Transforming the Paradigm for Lipid Lowering. JAMA Cardiol. 2021 Dec 01;6(12):1414. doi: 10.1001/jamacardio.2021.3517. PMID: 34550298.
Copy Download .nbib Format: NLM
Frequency, Characteristics, and Outcomes of Endovascular Thrombectomy in Patients With Stroke Beyond 6 Hours of Onset in US Clinical Practice.

Stroke

Zachrison KS, Schwamm LH, Xu H, Matsouaka R, Shah S, Smith EE, Xian Y, Fonarow GC, Saver J.
PMID: 34470490
Stroke. 2021 Dec;52(12):3805-3814. doi: 10.1161/STROKEAHA.121.034069. Epub 2021 Sep 02.

BACKGROUND AND PURPOSE: In 2018, 2 randomized controlled trials showed the benefit of endovascular thrombectomy (EVT) in acute ischemic stroke patients treated 6 to 24 hours from last known well using imaging-guided selection. However, little is known about outcomes...

Cite
Zachrison KS, Schwamm LH, Xu H, et al. Frequency, Characteristics, and Outcomes of Endovascular Thrombectomy in Patients With Stroke Beyond 6 Hours of Onset in US Clinical Practice. Stroke. 2021;52(12):3805-3814doi: 10.1161/STROKEAHA.121.034069.
Zachrison, K. S., Schwamm, L. H., Xu, H., Matsouaka, R., Shah, S., Smith, E. E., Xian, Y., Fonarow, G. C., & Saver, J. (2021). Frequency, Characteristics, and Outcomes of Endovascular Thrombectomy in Patients With Stroke Beyond 6 Hours of Onset in US Clinical Practice. Stroke, 52(12), 3805-3814. https://doi.org/10.1161/STROKEAHA.121.034069
Zachrison, Kori S, et al. "Frequency, Characteristics, and Outcomes of Endovascular Thrombectomy in Patients With Stroke Beyond 6 Hours of Onset in US Clinical Practice." Stroke vol. 52,12 (2021): 3805-3814. doi: https://doi.org/10.1161/STROKEAHA.121.034069
Zachrison KS, Schwamm LH, Xu H, Matsouaka R, Shah S, Smith EE, Xian Y, Fonarow GC, Saver J. Frequency, Characteristics, and Outcomes of Endovascular Thrombectomy in Patients With Stroke Beyond 6 Hours of Onset in US Clinical Practice. Stroke. 2021 Dec;52(12):3805-3814. doi: 10.1161/STROKEAHA.121.034069. Epub 2021 Sep 02. PMID: 34470490.
Copy Download .nbib Format: NLM
National Trends in Heart Failure Hospitalizations and Readmissions From 2010 to 2017.

JAMA cardiology

Agarwal MA, Fonarow GC, Ziaeian B.
PMID: 33566058
JAMA Cardiol. 2021 Aug 01;6(8):952-956. doi: 10.1001/jamacardio.2020.7472.

IMPORTANCE: Previous studies have described the secular trends of overall heart failure (HF) hospitalizations, but the literature describing the national trends of unique index hospitalizations and readmission visits for the primary management of HF is lacking.OBJECTIVES: To examine contemporary...

Cite
Agarwal MA, Fonarow GC, Ziaeian B. National Trends in Heart Failure Hospitalizations and Readmissions From 2010 to 2017. JAMA Cardiol. 2021;6(8):952-956doi: 10.1001/jamacardio.2020.7472.
Agarwal, M. A., Fonarow, G. C., & Ziaeian, B. (2021). National Trends in Heart Failure Hospitalizations and Readmissions From 2010 to 2017. JAMA cardiology, 6(8), 952-956. https://doi.org/10.1001/jamacardio.2020.7472
Agarwal, Manyoo A, et al. "National Trends in Heart Failure Hospitalizations and Readmissions From 2010 to 2017." JAMA cardiology vol. 6,8 (2021): 952-956. doi: https://doi.org/10.1001/jamacardio.2020.7472
Agarwal MA, Fonarow GC, Ziaeian B. National Trends in Heart Failure Hospitalizations and Readmissions From 2010 to 2017. JAMA Cardiol. 2021 Aug 01;6(8):952-956. doi: 10.1001/jamacardio.2020.7472. PMID: 33566058; PMCID: PMC7876620.
Copy Download .nbib Format: NLM
Sodium-glucose co-transporter 2 inhibitors as an early, first line therapy in patients with heart failure and reduced ejection fraction.

European journal of heart failure

Tomasoni D, Fonarow GC, Adamo M, Anker SD, Butler J, Coats AJ, Filippatos G, Greene SJ, McDonagh TA, Ponikowski P, Rosano G, Seferovic P, Vaduganathan M, Voors AA, Metra M.
PMID: 34894038
Eur J Heart Fail. 2021 Dec 10; doi: 10.1002/ejhf.2397. Epub 2021 Dec 10.

Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been recently recommended as a foundational therapy for patients with heart failure (HF) and reduced ejection fraction (HFrEF) because of their favourable effects on mortality, clinical events and quality of life. While clinical...

Cite
Tomasoni D, Fonarow GC, Adamo M, et al. Sodium-glucose co-transporter 2 inhibitors as an early, first line therapy in patients with heart failure and reduced ejection fraction. Eur J Heart Fail. 2021;doi: 10.1002/ejhf.2397.
Tomasoni, D., Fonarow, G. C., Adamo, M., Anker, S. D., Butler, J., Coats, A. J., Filippatos, G., Greene, S. J., McDonagh, T. A., Ponikowski, P., Rosano, G., Seferovic, P., Vaduganathan, M., Voors, A. A., & Metra, M. (2021). Sodium-glucose co-transporter 2 inhibitors as an early, first line therapy in patients with heart failure and reduced ejection fraction. European journal of heart failure, . https://doi.org/10.1002/ejhf.2397
Tomasoni, Daniela, et al. "Sodium-glucose co-transporter 2 inhibitors as an early, first line therapy in patients with heart failure and reduced ejection fraction." European journal of heart failure vol. (2021). doi: https://doi.org/10.1002/ejhf.2397
Tomasoni D, Fonarow GC, Adamo M, Anker SD, Butler J, Coats AJ, Filippatos G, Greene SJ, McDonagh TA, Ponikowski P, Rosano G, Seferovic P, Vaduganathan M, Voors AA, Metra M. Sodium-glucose co-transporter 2 inhibitors as an early, first line therapy in patients with heart failure and reduced ejection fraction. Eur J Heart Fail. 2021 Dec 10; doi: 10.1002/ejhf.2397. Epub 2021 Dec 10. PMID: 34894038.
Copy Download .nbib Format: NLM
Is the Left Ventricular Ejection Fraction Measurement Still Preeminent?-New Measures to Quantify Subclinical Systolic Dysfunction.

JAMA cardiology

Yancy CW, Fonarow GC.
PMID: 33729426
JAMA Cardiol. 2021 May 01;6(5):521. doi: 10.1001/jamacardio.2021.0143.

No abstract available.

Cite
Yancy CW, Fonarow GC. Is the Left Ventricular Ejection Fraction Measurement Still Preeminent?-New Measures to Quantify Subclinical Systolic Dysfunction. JAMA Cardiol. 2021;6(5):521doi: 10.1001/jamacardio.2021.0143.
Yancy, C. W., & Fonarow, G. C. (2021). Is the Left Ventricular Ejection Fraction Measurement Still Preeminent?-New Measures to Quantify Subclinical Systolic Dysfunction. JAMA cardiology, 6(5), 521. https://doi.org/10.1001/jamacardio.2021.0143
Yancy, Clyde W, and Fonarow, Gregg C. "Is the Left Ventricular Ejection Fraction Measurement Still Preeminent?-New Measures to Quantify Subclinical Systolic Dysfunction." JAMA cardiology vol. 6,5 (2021): 521. doi: https://doi.org/10.1001/jamacardio.2021.0143
Yancy CW, Fonarow GC. Is the Left Ventricular Ejection Fraction Measurement Still Preeminent?-New Measures to Quantify Subclinical Systolic Dysfunction. JAMA Cardiol. 2021 May 01;6(5):521. doi: 10.1001/jamacardio.2021.0143. PMID: 33729426.
Copy Download .nbib Format: NLM
Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database.

JAMA cardiology

Sumarsono A, Lalani HS, Vaduganathan M, Navar AM, Fonarow GC, Das SR, Pandey A.
PMID: 32902560
JAMA Cardiol. 2021 Jan 01;6(1):92-96. doi: 10.1001/jamacardio.2020.3723.

IMPORTANCE: Low-density lipoprotein cholesterol (LDL-C)-lowering therapies are a cornerstone of prevention in atherosclerotic cardiovascular disease. With the introduction of generic formulations and the release of new therapies, including proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, contemporary Medicare utilization of...

Cite
Sumarsono A, Lalani HS, Vaduganathan M, et al. Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database. JAMA Cardiol. 2021;6(1):92-96doi: 10.1001/jamacardio.2020.3723.
Sumarsono, A., Lalani, H. S., Vaduganathan, M., Navar, A. M., Fonarow, G. C., Das, S. R., & Pandey, A. (2021). Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database. JAMA cardiology, 6(1), 92-96. https://doi.org/10.1001/jamacardio.2020.3723
Sumarsono, Andrew, et al. "Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database." JAMA cardiology vol. 6,1 (2021): 92-96. doi: https://doi.org/10.1001/jamacardio.2020.3723
Sumarsono A, Lalani HS, Vaduganathan M, Navar AM, Fonarow GC, Das SR, Pandey A. Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database. JAMA Cardiol. 2021 Jan 01;6(1):92-96. doi: 10.1001/jamacardio.2020.3723. PMID: 32902560; PMCID: PMC7489407.
Copy Download .nbib Format: NLM
Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure.

JAMA cardiology

Bassi NS, Ziaeian B, Yancy CW, Fonarow GC.
PMID: 32374344
JAMA Cardiol. 2020 Aug 01;5(8):948-951. doi: 10.1001/jamacardio.2020.0898.

IMPORTANCE: Sodium-glucose cotransporter 2 inhibitor (SGLT2-i) therapy provided incremental survival benefit to patients with heart failure and reduced ejection fraction (HFrEF) who received guideline-directed medical therapy regardless of type 2 diabetes status in a recent clinical trial. To date,...

Cite
Bassi NS, Ziaeian B, Yancy CW, et al. Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure. JAMA Cardiol. 2020;5(8):948-951doi: 10.1001/jamacardio.2020.0898.
Bassi, N. S., Ziaeian, B., Yancy, C. W., & Fonarow, G. C. (2020). Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure. JAMA cardiology, 5(8), 948-951. https://doi.org/10.1001/jamacardio.2020.0898
Bassi, Nikhil S, et al. "Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure." JAMA cardiology vol. 5,8 (2020): 948-951. doi: https://doi.org/10.1001/jamacardio.2020.0898
Bassi NS, Ziaeian B, Yancy CW, Fonarow GC. Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure. JAMA Cardiol. 2020 Aug 01;5(8):948-951. doi: 10.1001/jamacardio.2020.0898. PMID: 32374344; PMCID: PMC7203666.
Copy Download .nbib Format: NLM
Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry.

Circulation. Heart failure

Khan MS, Greene SJ, Hellkamp AS, DeVore AD, Shen X, Albert NM, Patterson JH, Spertus JA, Thomas LE, Williams FB, Hernandez AF, Fonarow GC, Butler J.
PMID: 34674536
Circ Heart Fail. 2021 Nov;14(11):e008351. doi: 10.1161/CIRCHEARTFAILURE.121.008351. Epub 2021 Oct 22.

BACKGROUND: Diuretics are a mainstay therapy for the symptomatic treatment of heart failure. However, in contemporary US outpatient practice, the degree to which diuretic dosing changes over time and the associations with clinical outcomes and health care resource utilization...

Cite
Khan MS, Greene SJ, Hellkamp AS, et al. Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry. Circ Heart Fail. 2021;14(11):e008351doi: 10.1161/CIRCHEARTFAILURE.121.008351.
Khan, M. S., Greene, S. J., Hellkamp, A. S., DeVore, A. D., Shen, X., Albert, N. M., Patterson, J. H., Spertus, J. A., Thomas, L. E., Williams, F. B., Hernandez, A. F., Fonarow, G. C., & Butler, J. (2021). Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry. Circulation. Heart failure, 14(11), e008351. https://doi.org/10.1161/CIRCHEARTFAILURE.121.008351
Khan, Muhammad Shahzeb, et al. "Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry." Circulation. Heart failure vol. 14,11 (2021): e008351. doi: https://doi.org/10.1161/CIRCHEARTFAILURE.121.008351
Khan MS, Greene SJ, Hellkamp AS, DeVore AD, Shen X, Albert NM, Patterson JH, Spertus JA, Thomas LE, Williams FB, Hernandez AF, Fonarow GC, Butler J. Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry. Circ Heart Fail. 2021 Nov;14(11):e008351. doi: 10.1161/CIRCHEARTFAILURE.121.008351. Epub 2021 Oct 22. PMID: 34674536.
Copy Download .nbib Format: NLM
Outcomes of Endovascular Therapy in Patients With Prestroke Mobility Impairment.

Stroke

Beekman R, Sun JL, Alhanti B, Schwamm LH, Smith EE, Bhatt DL, Xian Y, Shah S, Lytle BL, Fonarow GC, Sheth KN.
PMID: 34517771
Stroke. 2021 Nov;52(11):e725-e728. doi: 10.1161/STROKEAHA.121.034464. Epub 2021 Sep 14.

BACKGROUND AND PURPOSE: Patients with prestroke mobility impairment (PSMI) were excluded from endovascular clinical trials. There are limited data regarding safety and outcomes of endovascular thrombectomy in this population. We used a large, national data set (Get With The...

Cite
Beekman R, Sun JL, Alhanti B, et al. Outcomes of Endovascular Therapy in Patients With Prestroke Mobility Impairment. Stroke. 2021;52(11):e725-e728doi: 10.1161/STROKEAHA.121.034464.
Beekman, R., Sun, J. L., Alhanti, B., Schwamm, L. H., Smith, E. E., Bhatt, D. L., Xian, Y., Shah, S., Lytle, B. L., Fonarow, G. C., & Sheth, K. N. (2021). Outcomes of Endovascular Therapy in Patients With Prestroke Mobility Impairment. Stroke, 52(11), e725-e728. https://doi.org/10.1161/STROKEAHA.121.034464
Beekman, Rachel, et al. "Outcomes of Endovascular Therapy in Patients With Prestroke Mobility Impairment." Stroke vol. 52,11 (2021): e725-e728. doi: https://doi.org/10.1161/STROKEAHA.121.034464
Beekman R, Sun JL, Alhanti B, Schwamm LH, Smith EE, Bhatt DL, Xian Y, Shah S, Lytle BL, Fonarow GC, Sheth KN. Outcomes of Endovascular Therapy in Patients With Prestroke Mobility Impairment. Stroke. 2021 Nov;52(11):e725-e728. doi: 10.1161/STROKEAHA.121.034464. Epub 2021 Sep 14. PMID: 34517771.
Copy Download .nbib Format: NLM
Transforming the Paradigm for Lipid Lowering.

JAMA cardiology

Navar AM, Fonarow GC.
PMID: 34550298
JAMA Cardiol. 2021 Sep 22; doi: 10.1001/jamacardio.2021.3517. Epub 2021 Sep 22.

No abstract available.

Cite
Navar AM, Fonarow GC. Transforming the Paradigm for Lipid Lowering. JAMA Cardiol. 2021;doi: 10.1001/jamacardio.2021.3517.
Navar, A. M., & Fonarow, G. C. (2021). Transforming the Paradigm for Lipid Lowering. JAMA cardiology, . https://doi.org/10.1001/jamacardio.2021.3517
Navar, Ann Marie, and Fonarow, Gregg C. "Transforming the Paradigm for Lipid Lowering." JAMA cardiology vol. (2021). doi: https://doi.org/10.1001/jamacardio.2021.3517
Navar AM, Fonarow GC. Transforming the Paradigm for Lipid Lowering. JAMA Cardiol. 2021 Sep 22; doi: 10.1001/jamacardio.2021.3517. Epub 2021 Sep 22. PMID: 34550298.
Copy Download .nbib Format: NLM
Outcomes of Medicare beneficiaries hospitalised with transient ischaemic attack and stratification using the ABCD.

Stroke and vascular neurology

Shah S, Liang L, Bhandary D, Johansson S, Smith EE, Bhatt DL, Fonarow GC, Khan ND, Peterson E, Bettger JP.
PMID: 33148542
Stroke Vasc Neurol. 2021 Jun;6(2):314-318. doi: 10.1136/svn-2020-000372. Epub 2020 Nov 04.

BACKGROUND: Long-term outcomes for Medicare beneficiaries hospitalised with transient ischaemic attack (TIA) and role of ABCDMETHODS: We identified 40 825 Medicare beneficiaries hospitalised from 2011 to 2014 for a TIA to a Get With The Guidelines (GWTG)-Stroke hospital and...

Cite
Shah S, Liang L, Bhandary D, et al. Outcomes of Medicare beneficiaries hospitalised with transient ischaemic attack and stratification using the ABCD. Stroke Vasc Neurol. 2020;6(2):314-318doi: 10.1136/svn-2020-000372.
Shah, S., Liang, L., Bhandary, D., Johansson, S., Smith, E. E., Bhatt, D. L., Fonarow, G. C., Khan, N. D., Peterson, E., & Bettger, J. P. (2021). Outcomes of Medicare beneficiaries hospitalised with transient ischaemic attack and stratification using the ABCD. Stroke and vascular neurology, 6(2), 314-318. https://doi.org/10.1136/svn-2020-000372
Shah, Shreyansh, et al. "Outcomes of Medicare beneficiaries hospitalised with transient ischaemic attack and stratification using the ABCD." Stroke and vascular neurology vol. 6,2 (2021): 314-318. doi: https://doi.org/10.1136/svn-2020-000372
Shah S, Liang L, Bhandary D, Johansson S, Smith EE, Bhatt DL, Fonarow GC, Khan ND, Peterson E, Bettger JP. Outcomes of Medicare beneficiaries hospitalised with transient ischaemic attack and stratification using the ABCD. Stroke Vasc Neurol. 2021 Jun;6(2):314-318. doi: 10.1136/svn-2020-000372. Epub 2020 Nov 04. PMID: 33148542; PMCID: PMC8258092.
Copy Download .nbib Format: NLM
Cost-effectiveness of PCSK9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden.

European heart journal. Quality of care & clinical outcomes

Landmesser U, Lindgren P, Hagström E, van Hout B, Villa G, Pemberton-Ross P, Arellano J, Svensson ME, Sibartie M, Fonarow GC.
PMID: 33063111
Eur Heart J Qual Care Clin Outcomes. 2020 Oct 16; doi: 10.1093/ehjqcco/qcaa072. Epub 2020 Oct 16.

AIMS: To assess the cost-effectiveness of PCSK9 inhibition with evolocumab added to standard-of-care lipid-lowering treatment (maximum tolerated dose [MTD] of statin and ezetimibe) in Swedish patients with a history of myocardial infarction (MI).METHODS AND RESULTS: Cost-effectiveness was evaluated using...

Cite
Landmesser U, Lindgren P, Hagström E, et al. Cost-effectiveness of PCSK9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden. Eur Heart J Qual Care Clin Outcomes. 2020;doi: 10.1093/ehjqcco/qcaa072.
Landmesser, U., Lindgren, P., Hagström, E., van Hout, B., Villa, G., Pemberton-Ross, P., Arellano, J., Svensson, M. E., Sibartie, M., & Fonarow, G. C. (2020). Cost-effectiveness of PCSK9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden. European heart journal. Quality of care & clinical outcomes, . https://doi.org/10.1093/ehjqcco/qcaa072
Landmesser, Ulf, et al. "Cost-effectiveness of PCSK9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden." European heart journal. Quality of care & clinical outcomes vol. (2020). doi: https://doi.org/10.1093/ehjqcco/qcaa072
Landmesser U, Lindgren P, Hagström E, van Hout B, Villa G, Pemberton-Ross P, Arellano J, Svensson ME, Sibartie M, Fonarow GC. Cost-effectiveness of PCSK9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden. Eur Heart J Qual Care Clin Outcomes. 2020 Oct 16; doi: 10.1093/ehjqcco/qcaa072. Epub 2020 Oct 16. PMID: 33063111.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 191 entries